Evidence map›Paper›PMID 40099449›Full record

ArticleJournal of proteome research2025

High-Throughput Site-Specific N-Glycosylation Profiling of Human Fibrinogen in Atrial Fibrillation.

Dinko Šoić, Domagoj Kifer, Janko Szavits-Nossan, Aleksandar Blivajs, Lovorka Đerek, Diana Rudan, Olga Gornik, Ivan Gudelj, Toma Keser

Abstract read
In one paragraph

Article in Journal of proteome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dinko ŠoićFaculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, 10000 Zagreb, Croatia.
Domagoj KiferFaculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, 10000 Zagreb, Croatia.
Janko Szavits-NossanMagdalena University Hospital for Cardiovascular Diseases, Radnička cesta 32, 10000 Zagreb, Croatia.
Aleksandar BlivajsDepartment of Cardiology, University Hospital Dubrava, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia.
Lovorka ĐerekClinical Department for Laboratory Diagnostics, University Hospital Dubrava, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia.
Diana RudanDepartment of Cardiology, University Hospital Dubrava, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia.
Olga GornikFaculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, 10000 Zagreb, Croatia.
Ivan GudeljFaculty of Biotechnology and Drug Development, University of Rijeka, Radmile Matejčić 2, 51000 Rijeka, Croatia.
Toma KeserFaculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, 10000 Zagreb, Croatia.ORCID 0000-0003-2759-3742

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrinogen is a major plasma glycoprotein involved in blood coagulation and inflammatory responses. Alterations in its glycosylation have been implicated in various pathological conditions; yet, its site-specific N-glycosylation profile remains largely unexplored in a clinical context. Here, we present a high-throughput LC-MS workflow for site-specific analysis of fibrinogen N-glycosylation using a cost-effective ethanol precipitation enrichment method. The method demonstrated good intra- and interplate repeatability (CV: 5% and 12%, respectively) and was validated through the first assessment of intraindividual temporal stability in healthy individuals, revealing consistent glycosylation patterns within individuals. Application to 181 atrial fibrillation (AF) patients and 52 healthy controls identified three gamma chain glycoforms significantly associated with AF. Most notably, increased levels of the asialylated N4H5, known to enhance fibrin bundle thickness and promote clot formation, suggest a potential mechanism linking glycosylation changes to the prothrombotic state in AF. Furthermore, fibrinogen sialylation showed strong associations with cardiovascular risk factors, including triglycerides, BMI, and glucose levels. Longitudinal analysis of 108 AF patients six months postcatheter ablation showed stability in the AF-associated glycan profile. Our findings establish fibrinogen glycosylation as a potential biomarker for cardiovascular conditions and demonstrate the utility of site-specific glycosylation analysis for clinical applications.

Indexed as

Atrial FibrillationFibrinogenAgedBiomarkersCase-Control StudiesChromatography, LiquidFemaleGlycosylationHigh-Throughput Screening AssaysHumansMaleMiddle AgedBiomarkersFibrinogenatrial fibrillationbiomarkercardiovascular diseasesfibrinogenglycoproteomicshigh throughputN-glycanN-glycosylation

Identifiers

PMID40099449
PMCPMC11976851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.